Fig. 1From: Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumabDisposition of patients by study arms and reasons for withdrawal. * Patients was excluded prior to drug administration (1 - IC withdrawal by subject; 1 – death)Back to article page